Nabeeh Lahood, MD
Allergy & Immunology · Tucson, AZNPI 1043314065
Payments from drug & device makers
Across 601 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$1K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Amgen$908
- Regeneron Healthcare Solutions, Inc.$781
- plus $5K from 28 others
What the payments were for
- Consulting fees$210%
- Food & beverage$12,63199%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $2,407 |
| CSL Behring | 59 | $1,489 |
| GSK | 89 | $1,331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $1,089 |
| Amgen | 43 | $908 |
| Regeneron Healthcare Solutions, Inc. | 39 | $781 |
| Sanofi | 32 | $748 |
| Novartis | 34 | $623 |
| Genentech USA, Inc. | 25 | $501 |
| Grifols USA, LLC | 22 | $419 |
| Pfizer | 39 | $390 |
| Teva Pharmaceuticals USA, Inc. | 20 | $322 |
| Pharming Healthcare, Inc. | 5 | $285 |
| Kaleo, Inc. | 6 | $148 |
| Bio Products Laboratory USA, Inc. | 11 | $144 |
| Shire North American Group Inc | 8 | $139 |
| Genentech, Inc. | 1 | $132 |
| Biocryst US Sales Co., LLC | 4 | $110 |
| Covis Pharma GmbH | 3 | $99 |
| Boehringer Ingelheim | 6 | $91 |
| Blueprint Medicines Corporation | 3 | $73 |
| GC Biopharma USA, Inc. | 5 | $72 |
| Optinose US, Inc. | 4 | $72 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Lilly USA, LLC | 2 | $55 |
| Kedrion Biopharma, Inc. | 3 | $53 |
| Mylan Specialty L.p. | 2 | $48 |
| Merck | 1 | $29 |
| LEO Pharma Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| ADMA Biomanufacturing LLC | 2 | $21 |
| Incyte Corporation | 1 | $16 |
| Circassia Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,735 in reported general payments places this provider in the 65th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 60 | $292,497 |
| Dupixent SyringeDupilumab | 54 | $233,097 |
| FasenraBenralizumab | 29 | $173,668 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 63 | $158,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 171 | $137,956 |
| TezspireTezepelumab-Ekko | 20 | $82,570 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $72,697 |
| XolairOmalizumab | 18 | $48,240 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $40,896 |
| Advair HfaFluticasone Propion/Salmeterol | 84 | $34,869 |
| SymbicortBudesonide/Formoterol Fumarate | 125 | $32,656 |
| Arnuity ElliptaFluticasone Furoate | 56 | $14,620 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $14,098 |
| DuleraMometasone/Formoterol | 30 | $13,928 |
| Epinephrine | 60 | $11,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire, Symbicort | $2,407 | $288,894174 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,331 | $193,471308 claims |
| CSL BehringHizentra | $1,489 | $158,74263 claims |
| Grifols USA, LLCGamunex-C | $419 | $72,69717 claims |
| Genentech, Inc.Xolair | $132 | $48,24018 claims |
| MerckDulera | $29 | $13,92830 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $322 | $7,24222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Tucson
- Tara CarrTucson$308K
- Heather CassellTucson$261K
- Pierre SakaliTucson$25K
- George MakolTucson$13K
- Nicole LahoodTucson$13K
- Martin BartelsTucson$7K
- Puneet ShroffTucson$4K
- Kudagal MurthyTucson$3K
- Anjali JainTucson$2K
- Kaitlyn LeaheyTucson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.